Gelonghui September 25th | Pures (301257.SZ) recently received a specific research on "What is the situation of new signed orders for the company in the first half of 2024?" The company stated that in the first half of 2024, the company's new signed untaxed contract amount was 0.429 billion yuan, a year-on-year decrease of 31.89%. This was mainly due to the structural and cyclical impact on the biomedical industry, which affected both the supply and demand sides, intensified competition within the industry, leading to a decrease in order prices. In order to achieve long-term sustainable profitable development, the company made choices regarding orders that did not meet certain profit indicators.
In the second quarter of 2024, market demand for orders gradually rebounded. The company strengthened its business expansion, reserved business personnel according to business needs, and the new signed untaxed contract amount in the second quarter of 2024 increased by 112.14% compared to the first quarter. As of the end of June 2024, the company's existing untaxed contract amount was 1.825 billion yuan, a year-on-year increase of 4.07%.
